MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
机构：[1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China[2]Translational Medicine, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China[3]Internal Medicine, Shandong Province Cancer Hospital, Jinan, China[4]Department of Thoracic Oncology II, Peking University Cancer Hospital, Beijing, China[5]The Second Department of Chemotherapy, Tumor Hospital of Guangxi Zhuang Autonomous Region, Nanning, China[6]Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China[7]Oncology Departmeng, Henan Provincial Peoples Hospital, Zhengzhou, China[8]Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China[9]Department of Respiratory Disease, Anhui Provincial Hospital, Hefei, China[10]Department I of Oncology Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China[11]Medical Department, Liaoning Cancer Hospital, Shengyang, China[12]Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Benbu, China[13]Department of Biological Therapy, Tianjin Cancer Institute & Hospital, Tianjin, China[14]Respiratory Medicine, The First Affiliated hospital, Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[15]General Department, Beijing Chest Hospital, Capital Medical University, Beijing, China[16]Medical Oncology, Innovent Biologics (Suzhou) Co., Ltd., Shanghai, China
第一作者机构：[1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
推荐引用方式(GB/T 7714)：
Y. Yang,J. Sun,Z. Wang,et al.MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)[J].ANNALS OF ONCOLOGY.2020,31:S1186-S1186.doi:10.1016/j.annonc.2020.08.2290.
APA：
Y. Yang,J. Sun,Z. Wang,J. Fang,Q. Yu...&L. Zhang.(2020).MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).ANNALS OF ONCOLOGY,31,
MLA：
Y. Yang,et al."MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)".ANNALS OF ONCOLOGY 31.(2020):S1186-S1186
医学